Company performance
Add to research
Current Price
as of May 21, 2025$25.41
P/E Ratio
N/A
Market Cap
$18.87B
Description
Add to research
Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.
Metrics
Add to research
Overview
- HQMiami, FL
- SectorHealth Technology
- IndustryBiotechnology
- TickerSMMT
- Price$25.41+4.18%
Trading Information
- Market cap$18.87B
- Float14.97%
- Average Daily Volume (1m)5,303,248
- Average Daily Volume (3m)4,041,988
- EPS-$0.33
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$62.91M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$66.83M
- EV$13.88B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B54.73
- Debt/Equity1.87
Documents
Add to research
SEC Filings
Earnings Calls